Cargando…
Rituximab in early systemic sclerosis
OBJECTIVES: (1) Hypothesis testing of the potency of rituximab (RTX) in preventing fibrotic complications and (2) assessing acceptability and feasibility of RTX in early systemic sclerosis (SSc). METHODS: A small, 24-month, randomised, double-blind, placebo-controlled, single-centre trial in patient...
Autores principales: | Boonstra, Maaike, Meijs, Jessica, Dorjée, Annemarie L, Marsan, Nina Ajmone, Schouffoer, Anne, Ninaber, Maarten K, Quint, Koen D, Bonte-Mineur, Femke, Huizinga, Tom W J, Scherer, Hans U, de Vries-Bouwstra, Jeska K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574444/ https://www.ncbi.nlm.nih.gov/pubmed/28879049 http://dx.doi.org/10.1136/rmdopen-2016-000384 |
Ejemplares similares
-
Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016) -
Evolution of Systemic Sclerosis–Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide
por: Ciaffi, Jacopo, et al.
Publicado: (2022) -
Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2020) -
New risk model is able to identify patients with a low risk of progression in systemic sclerosis
por: van Leeuwen, Nina Marijn, et al.
Publicado: (2021) -
Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis
por: Wortel, Corrie M, et al.
Publicado: (2023)